Final Approval for Saxenda in Europe
March 24, 2015 — The European Commission granted final approval late yesterday for Novo Nordisk’s Saxenda brand of liraglutide 3mg to treat obesity. Saxenda is the first obesity treatment in nearly a decade to receive approval in Europe. Novo Nordisk is already in the final stages of preparing to launch Saxenda in the U.S., where it was approved late last […]
